Skip to main content

2020 Year in Review - AML

For patients with AML in the QUAZAR AML-001 trial who relapsed with 5% to 15% blasts on-study, an escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients. Read More ›

A study comparing gilteritinib + azacitidine with azacitidine alone in patients with newly diagnosed, FLT3-mutated AML showed no new safety signals associated with gilteritinib. The safety cohort showed a composite response rate of 67% for gilteritinib + azacitidine. Read More ›

Adjusted simulated treatment comparisons showed that the overall survival hazard ratios favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC numerically, but not statistically. Read More ›

This study of 19 patients with IDH2-mutated acute myeloid leukemia indicates that a combination of the IDH2 inhibitor ivosidenib combined with venetoclax with or without azacitidine is effective and well-tolerated, warranting further study. Read More ›

In this study, in patients with relapsed/refractory or secondary myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), decitabine + ipilimumab exhibited encouraging clinical activity, with an anticipated adverse event profile. Read More ›

This phase 1b study demonstrated that adding the novel macrophage-targeting immunotherapy magrolimab to azacitidine is well-tolerated and effective for treating patients with AML who are unfit for chemotherapy. Read More ›

Venetoclax added to the low-intensity backbone of cladribine plus low-dose cytarabine (Ara-C) alternating with 5-azacitidine was an effective regimen that was well-tolerated among patients with acute myeloid leukemia. Read More ›

MBG453 combined with decitabine or azacitidine was safe and well-tolerated by patients with myelodysplastic syndrome or acute myeloid leukemia. Both combinations showed encouraging antileukemic activity and response rates. Read More ›

Among patients with relapsed/refractory acute myeloid leukemia, CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity. Read More ›

Superior outcomes were observed for older patients with AML receiving decitabine + venetoclax for 10 days versus intensive chemotherapy in a propensity score–matched analysis, particularly for those at high risk for treatment-related mortality. Read More ›

Page 2 of 3